Cargando…

Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway

BACKGROUND: Peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligands have been widely shown to correlate with epithelial-mesenchymal transition (EMT) and cancer progression. Lobeglitazone (LGZ) is a novel ligand of PPAR-γ; and its role in EMT and metastasis in papillary thyroid carcinoma (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Jun-Qing, Han, Jeong-Sun, Ha, Jeonghoon, Baek, Han-Sang, Lim, Dong-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566138/ https://www.ncbi.nlm.nih.gov/pubmed/34645125 http://dx.doi.org/10.3803/EnM.2021.1155

Ejemplares similares

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Bae, Kwi-Hyun, et al.
Publicado: (2017)

No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects
por: Kim, Yu Kyong, et al.
Publicado: (2021)

Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma
por: Lu, Zhong-Wu, et al.
Publicado: (2020)

Peroxisome Proliferator-Activated Receptor-Gamma Agonists Suppress Tissue Factor Overexpression in Rat Balloon Injury Model with Paclitaxel Infusion
por: Park, Jun-Bean, et al.
Publicado: (2011)

Differential Effects of Estrogen Receptor Alpha and Beta on Endogenous Ligands of Peroxisome Proliferator-Activated Receptor Gamma in Papillary Thyroid Cancer
por: Yang, Shucai, et al.
Publicado: (2021)

Interaction of MRPL9 and GGCT Promotes Cell Proliferation and Migration by Activating the MAPK/ERK Pathway in Papillary Thyroid Cancer
por: Zhang, Hui-Min, et al.
Publicado: (2022)

Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases
por: Sharma, Vinesh, et al.
Publicado: (2022)

Association of Hyperparathyroidism and Papillary Thyroid Cancer: A Multicenter Retrospective Study
por: Jeong, Chaiho, et al.
Publicado: (2020)

Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
por: Jang, Jun Young, et al.
Publicado: (2018)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

A Role for Peroxisome Proliferator-Activated Receptor Gamma Agonists in Counteracting the Degeneration of Cardiovascular Grafts
por: Assmann, Anna Kathrin, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Active Surveillance Compared to Early Surgery in Small Papillary Thyroid Cancer: A Systemic Review
por: Baek, Han-sang, et al.
Publicado: (2021)

Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages
por: Jeong, Dabin, et al.
Publicado: (2021)

Polyacetylenes from Notopterygium incisum–New Selective Partial Agonists of Peroxisome Proliferator-Activated Receptor-Gamma
por: Atanasov, Atanas G., et al.
Publicado: (2013)

Identification of Isosilybin A from Milk Thistle Seeds as an Agonist of Peroxisome Proliferator-Activated Receptor Gamma
por: Pferschy-Wenzig, Eva-Maria, et al.
Publicado: (2014)

Role of peroxisome proliferator‐activated receptor gamma agonist in improving hepatic steatosis: Possible molecular mechanism
por: Park, Cheol‐Young, et al.
Publicado: (2012)

Polyyne Hybrid Compounds from Notopterygium incisum with Peroxisome Proliferator-Activated Receptor Gamma Agonistic Effects
por: Liu, Xin, et al.
Publicado: (2014)

Cost-Effectiveness of Active Surveillance Compared to Early Surgery of Small Papillary Thyroid Cancer: A Retrospective Study on a Korean Population
por: Baek, Han-Sang, et al.
Publicado: (2023)

Calcification Patterns in Papillary Thyroid Carcinoma are Associated with Changes in Thyroid Hormones and Coronary Artery Calcification
por: Ha, Jeonghoon, et al.
Publicado: (2018)

Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
por: Seo, Hye-Young, et al.
Publicado: (2023)

Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma
por: Park, Hyung Kyu, et al.
Publicado: (2015)

Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists Using 3D-QSAR and Molecular Docking
por: Jian, Yaning, et al.
Publicado: (2018)

Peroxisome proliferator-activated receptor gamma agonist as a novel treatment for interstitial cystitis: A rat model
por: Mahal, Amandeep, et al.
Publicado: (2018)

Effects of Peroxisome Proliferator-Activated Receptor-Gamma Agonists on Cognitive Function: A Systematic Review and Meta-Analysis
por: Zhong, Hongfei, et al.
Publicado: (2023)

Melatonin and Its Metabolites Can Serve as Agonists on the Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor Gamma
por: Slominski, Andrzej T., et al.
Publicado: (2023)

Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
por: Youssef, Jihan, et al.
Publicado: (2002)

THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis
por: Tomita, Tetsuya, et al.
Publicado: (2006)

Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression
por: Burrage, Peter S, et al.
Publicado: (2008)

Benzoxazinones as Human Peroxisome Proliferator Activated Receptor Gamma (PPARγ) Agonists: A Docking Study Using Glide
por: Das, N., et al.
Publicado: (2011)

Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update
por: Khan, Mahmood Ahmad, et al.
Publicado: (2019)

Peroxisome Proliferator-Activated Receptor-gamma agonists exhibit anti-inflammatory and antiviral effects in an EcoHIV mouse model
por: Omeragic, Amila, et al.
Publicado: (2019)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Effect of Peroxisome Proliferator-Activated Receptor Gamma Agonist (Pioglitazone) and Methotrexate on Disease Activity in Rheumatoid Arthritis (Experimental and Clinical Study)
por: Shahin, Dina, et al.
Publicado: (2011)

Protective effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on endotoxin-induced acute lung injury in rats
por: Liu, D, et al.
Publicado: (2005)

Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis
por: Alatas, Fatima Safira, et al.
Publicado: (2020)

Combination of peroxisome proliferator–activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells
por: Chen, Jui-Yu, et al.
Publicado: (2020)

The role of peroxisome proliferator-activated receptor gamma in prostate cancer
por: Elix, Catherine, et al.
Publicado: (2018)

Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
por: Choung, Sorim, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c593tidrjdbc8n1kjs3dg51dke